CYP17 gene polymorphism in relation to breast cancer risk: a case-control study
2005

CYP17 Gene and Breast Cancer Risk

Sample size: 3046 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kristjana Einarsdóttir, Tove Rylander-Rudqvist, Keith Humphreys, Susanne Ahlberg, Gudrun Jonasdottir, Elisabete Weiderpass, Kee Seng Chia, Magnus Ingelman-Sundberg, Ingemar Persson, Jianjun Liu, Per Hall, Sara Wedrén

Primary Institution: Karolinska Institutet

Hypothesis

Does the CYP17 c.1-34T>C polymorphism influence breast cancer risk in postmenopausal women?

Conclusion

CYP17 c.1-34T>C does not appear to have any major influence on breast cancer risk.

Supporting Evidence

  • The study included a large sample size of 1,544 breast cancer cases and 1,502 controls.
  • No overall association was found between the CYP17 polymorphism and breast cancer risk.
  • An interaction with age at menarche was detected but considered a chance finding.

Takeaway

The study looked at a gene that might affect breast cancer risk but found that it doesn't really change the chances of getting breast cancer.

Methodology

The study genotyped 1,544 breast cancer cases and 1,502 controls for the CYP17 c.1-34T>C polymorphism using logistic regression models.

Potential Biases

Potential bias due to over-sampling of menopausal hormone users and diabetics.

Limitations

The study focused only on postmenopausal women, which may limit the generalizability of the findings.

Participant Demographics

All participants were postmenopausal Swedish women.

Statistical Information

P-Value

0.026

Confidence Interval

95% CI 0.8–1.3

Statistical Significance

p=0.026

Digital Object Identifier (DOI)

10.1186/bcr1319

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication